CN111728096A - 大鼠高脂血症模型饲料及其制备方法和应用 - Google Patents
大鼠高脂血症模型饲料及其制备方法和应用 Download PDFInfo
- Publication number
- CN111728096A CN111728096A CN202010683023.2A CN202010683023A CN111728096A CN 111728096 A CN111728096 A CN 111728096A CN 202010683023 A CN202010683023 A CN 202010683023A CN 111728096 A CN111728096 A CN 111728096A
- Authority
- CN
- China
- Prior art keywords
- rat
- feed
- model feed
- hyperlipidemia model
- model
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 30
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000008188 pellet Substances 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 9
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229950000329 thiouracil Drugs 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000010276 construction Methods 0.000 claims abstract description 3
- 239000004519 grease Substances 0.000 claims abstract description 3
- 150000002632 lipids Chemical class 0.000 claims description 8
- 235000019197 fats Nutrition 0.000 claims description 7
- 239000011812 mixed powder Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 235000019198 oils Nutrition 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 5
- 229920002261 Corn starch Polymers 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 claims description 4
- 229960004874 choline bitartrate Drugs 0.000 claims description 4
- 229940110456 cocoa butter Drugs 0.000 claims description 4
- 235000019868 cocoa butter Nutrition 0.000 claims description 4
- 239000008120 corn starch Substances 0.000 claims description 4
- 229960003067 cystine Drugs 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000011552 rat model Methods 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 230000001788 irregular Effects 0.000 claims description 3
- 210000003855 cell nucleus Anatomy 0.000 claims description 2
- 210000005229 liver cell Anatomy 0.000 claims description 2
- 210000003934 vacuole Anatomy 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 241000700159 Rattus Species 0.000 abstract description 48
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 10
- 230000002496 gastric effect Effects 0.000 abstract description 6
- 238000010171 animal model Methods 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 239000003833 bile salt Substances 0.000 abstract description 2
- 230000008506 pathogenesis Effects 0.000 abstract description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 101710095342 Apolipoprotein B Proteins 0.000 description 5
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 5
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 208000003532 hypothyroidism Diseases 0.000 description 5
- 230000002989 hypothyroidism Effects 0.000 description 5
- 239000005495 thyroid hormone Substances 0.000 description 5
- 229940036555 thyroid hormone Drugs 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 3
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 3
- 102000043296 Lipoprotein lipases Human genes 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- -1 compound vitamin Chemical class 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/50—Feeding-stuffs specially adapted for particular animals for rodents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/168—Steroids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/10—Shaping or working-up of animal feeding-stuffs by agglomeration; by granulation, e.g. making powders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Environmental Sciences (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
Abstract
本发明属于实验动物技术领域,尤其涉及大鼠高脂血症模型饲料的制备方法,精确称取基础饲料、1.25%的胆固醇和0.2%硫脲嘧啶进行混合;加入40%热量比的油脂进行搅拌;加入水分搅拌混合,通过制粒机进行制粒,获得软颗粒饲料;进行低温烘干水分,获得大鼠高脂血症的模型饲料。本发明还提供了大鼠高脂血症模型饲料及其应用。本发明降低了胆固醇的含量,调低了胆盐和硫脲嘧啶,采用本发明提供的大鼠高脂血症模型饲料构建模型符合高脂血症的人类发病机制,保证建模的成功率基础上,加快了模型建立进程,缩短了实验周期,从而提高了实验效率。此外,本发明的大鼠高脂血症模型饲料使大鼠自由采食,无需灌胃,如此不仅符合动物伦理,也节约实施灌胃的人力成本。
Description
技术领域
本发明属于实验动物技术领域,尤其涉及大鼠高脂血症模型饲料及其制备方法和应用。
背景技术
高脂血症仍是未被攻克的重大疑难病,是心脑血管病的重要诱因,严重威胁着我国人民的健康。研究高脂血症的关键是选择理想的高脂血症动物模型,大鼠是目前研究高脂血症最常用的动物,能较好地反映多种实验因素对脂质吸收、分解及合成等代谢环节的影响,同时具有成本低、易于饲养、取血量大等优点,因而被作为高脂血症动物模型广泛用于降脂药物的研究。传统的高脂血症模型建立方法是采用长期普通高脂饲料喂养大鼠来建立高脂血症动物模型,方法并不科学,大鼠受饲养条件的限制,不可能单独饲养,随着造模时间的延长造成进食高脂饲料的不均衡,产生许多不确定因素无法定量,具有一定的局限性。
发明内容
针对上述现有技术的不足,本发明提供了大鼠高脂血症模型饲料的制备方法,目的是为了解决现有高脂血症模型建立方法中,采用长期普通高脂饲料喂养,造成大鼠受饲养条件的限制,不可能单独饲养,随着造模时间的延长造成进食高脂饲料的不均衡,产生许多不确定因素无法定量,具有一定的局限性的技术问题。本发明还提供了大鼠高脂血症模型饲料及其应用。
本发明提供了大鼠高脂血症模型饲料的制备方法,具体技术方案如下:
大鼠高脂血症模型饲料的制备方法,包括如下步骤:
S1,精确称取基础饲料、1.25%质量比的胆固醇和0.2%质量比硫脲嘧啶进行混合,获得混合粉料;
S2,步骤S1中的混合粉料加入40%热量比的油脂进行搅拌,获得油料混合物;
S3,步骤S2中的油料混合物加入水分搅拌混合,通过制粒机进行制粒,获得软颗粒饲料;
S4,将步骤S3中的软颗粒饲料进行低温烘干水分,获得大鼠高脂血症的模型饲料。
在某些实施方式中,步骤S1中,所述基础饲料按质量百分比计包括22.13%蛋白粉、0.33%胱氨酸、23.46%玉米淀粉、7.86%麦芽糊精、12.51%蔗糖、5.53%纤维素、4.98%复合矿物质、1.11%复合维生素和0.22%酒石酸氢胆碱。
在某些实施方式中,步骤S2中,所述油脂按质量比计包括2.77%大豆油和17.15%的可可脂。
在某些实施方式中,步骤S3中,所述软颗粒饲料的粒径为10-15mm。
在某些实施方式中,步骤S4中,所述烘干的温度为26摄氏度,时间为48h。
本发明还提供了大鼠高脂血症模型饲料,根据上述的方法制备的大鼠高脂血症的模型饲料。
本发明还提供了大鼠高脂血症模型饲料的应用,用于构建大鼠高脂血症模型,连续给SD大鼠饲喂上述的大鼠高脂血症的模型饲料15天,自由饮水,大鼠肝脏超过50%的肝细胞肿胀,形态不规则,排列紊乱,内充满的脂滴空泡,将细胞核挤向一侧,即大鼠高脂血症模型构建完成。
本发明具有以下有益效果:传统的高脂饮食可以引起肝脏脂肪的堆积,大量胆固醇的摄入可以引起血脂四项的异常,添加一定量的胆酸钠可以有效促进肠道内胆固醇、脂类物质的消化和吸收。氧化应激及胰岛素抵抗在血脂异常代谢的发生发展中起着非常重要的作用,大量硫脲嘧啶的摄入可以引起甲减,甲减患者体内总胆固醇(total cholesterol,TC)、低密度脂蛋白(low densitylipo protein,LDL)、甘油三酯(triglyceride,TG)及载脂蛋白B(apolipoprotein B,ApoB)水平都会明显增高,甲状腺激素(thyroid hormone,TH)能增加LDL受体数目,甲减时TH下降,LDL清除率下降,使LDL升高。TH对脂蛋白脂酶(lipoproteinlipase,LPL)活性也有影响,甲减时LPL活性下降,TG清除率下降,胆固醇、胆酸排泄减少,造成TCTG升高。TH仅影响ApoB清除,不影响ApoB产生,甲减时ApoB升高。
本发明在保证正常生长的各种原料基础上添加了1.25%胆固醇,0.5%胆酸钠,0.2%硫脲嘧啶,40%热量比脂肪,降低了胆固醇的含量,调低了胆盐和硫脲嘧啶,采用本发明提供的大鼠高脂血症模型饲料构建模型符合高脂血症的人类发病机制,加快模型建立进程,缩短了实验周期,从而提高了实验效率。此外,本发明提供的大鼠高脂血症模型饲料使大鼠自由采食,不需要灌胃,如此不仅符合动物伦理,也节约实施灌胃的人力成本。
附图说明
图1是本发明提供的大鼠高脂血症模型饲料的制备方法的流程图;
图2是对照组和实施例组大鼠2周后血脂四项变化对比图;
图3是对照组和实施例组大鼠体重变化对比图。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚明白,以下结合具体实施例,并参照附图1-3,对本发明进一步详细说明。
实施例
本实施例提供的大鼠高脂血症模型饲料的制备方法,具体技术方案如下:
大鼠高脂血症模型饲料的制备方法,包括如下步骤:
S1,精确称取如表1所示的原料,按质量比计,将22.13%蛋白粉、0.33%胱氨酸、23.46%玉米淀粉、7.86%麦芽糊精、12.51%蔗糖、5.53%纤维素、4.98%复合矿物质、1.11%复合维生素、0.22%酒石酸氢胆碱、1.25%胆固醇和0.2%硫脲嘧啶进行混合,获得混合粉料;
S2,步骤S1中的混合粉料加入2.77%大豆油和17.15%的可可脂(40%热量比的油脂)进行搅拌,获得油料混合物;
S3,步骤S2中的油料混合物加入水分搅拌混合,通过制粒机进行制粒,获得粒径为10-15mm的软颗粒饲料,本实施例中软颗粒饲料的粒径为12mm左右;
S4,将步骤S3中的软颗粒饲料在26摄氏度下进行低温烘干(烘干的温度为26摄氏度,时间为48小时)水分,获得大鼠高脂血症的模型饲料。
表1本实施例提供的大鼠高脂血症模型饲料的称量原料
重量 | 热量 | |
单位 | 克 | 千卡 |
蛋白粉 | 200 | 800 |
胱氨酸 | 3 | 12 |
玉米淀粉 | 212 | 848 |
麦芽糊精 | 71 | 284 |
蔗糖 | 113 | 452 |
纤维素 | 50 | 0 |
大豆油 | 25 | 225 |
可可脂 | 155 | 1395 |
复合矿物质 | 45 | 0 |
复合维生素 | 10 | 40 |
酒石酸氢胆碱 | 2 | 0 |
胆固醇 | 11.25 | 0 |
硫脲嘧啶 | 1.9 | 0 |
胆酸钠 | 4.5 | 0 |
合计 | 903.65 | 4056 |
本实施例还提供利用上述方法制备的大鼠高脂血症的模型饲料。
随机选取SD大鼠60只,将SD大鼠分为对照组和实施例组(高脂组),每组30只,每组大鼠分笼喂养,可自由进食饮水,其中对照组喂食基础饲料,实施例组喂食本实施例提供的大鼠高脂血症的模型饲料,共饲养15天,实验室12h昼夜循环,温度(25±2)℃,相对湿度50%-70%。观察高脂饲料对大鼠体质量、摄食量、TC、TG、HDL-C、LDL-C等参数的影响,进而评价高脂饮食诱导大鼠高脂血症模型的影响。实验前及以后每天称量体重,每天测定血清甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)。计量资料两组间均数比较用t检验,多组间均数比较应用方差分析;应用SPSS10.0统计软件包分析,显著性水平定于0.05。
如图2所示,实施例组的大鼠喂养2周后,血脂TC和LDL-C从极低水平迅速升高,大鼠肝脏超过50%的肝细胞肿胀,形态不规则,排列紊乱,内充满的脂滴空泡,将细胞核挤向一侧,从而显示高脂血症已经形成,而TG变化没有明显趋势,即TG变化与高脂饮食之间无相关性。如图3所示,对照组和实施例组的体重在长期喂养的过程中差异不大,减少了体重对于血脂影响这项干扰因素。本发明降低了胆固醇的含量,调低了胆盐和硫脲嘧啶,采用本发明提供的大鼠高脂血症模型饲料构建模型符合高脂血症的人类发病机制,保证建模的成功率基础上,加快了模型建立进程,缩短了实验周期,从而提高了实验效率。此外,本发明提供的大鼠高脂血症模型饲料使大鼠自由采食,不需要灌胃,如此不仅符合动物伦理,也节约实施灌胃的人力成本。
上述仅本发明较佳可行实施例,并非是对本发明的限制,本发明也并不限于上述举例,本技术领域的技术人员,在本发明的实质范围内,所作出的变化、改型、添加或替换,也应属于本发明的保护范围。
Claims (7)
1.大鼠高脂血症模型饲料的制备方法,其特征在于,包括如下步骤:
S1,精确称取基础饲料、1.25%质量比的胆固醇和0.2%质量比硫脲嘧啶进行混合,获得混合粉料;
S2,步骤S1中的混合粉料加入40%热量比的油脂进行搅拌,获得油料混合物;
S3,步骤S2中的油料混合物加入水分搅拌混合,通过制粒机进行制粒,获得软颗粒饲料;
S4,将步骤S3中的软颗粒饲料进行低温烘干水分,获得大鼠高脂血症的模型饲料。
2.根据权利要求1所述的大鼠高脂血症模型饲料的制备方法,其特征在于,步骤S1中,所述基础饲料按质量百分比计包括22.13%蛋白粉、0.33%胱氨酸、23.46%玉米淀粉、7.86%麦芽糊精、12.51%蔗糖、5.53%纤维素、4.98%复合矿物质、1.11%复合维生素和0.22%酒石酸氢胆碱。
3.根据权利要求1所述的大鼠高脂血症模型饲料的制备方法,其特征在于,步骤S2中,所述油脂按质量比计包括2.77%大豆油和17.15%的可可脂。
4.根据权利要求1所述的大鼠高脂血症模型饲料的制备方法,其特征在于,步骤S3中,所述软颗粒饲料的粒径为10-15mm。
5.根据权利要求1所述的大鼠高脂血症模型饲料的制备方法,其特征在于,步骤S4中,所述烘干的温度为26摄氏度,时间为48小时。
6.大鼠高脂血症模型饲料,其特征在于,根据权利要求1-5任一项所述的方法制备的大鼠高脂血症的模型饲料。
7.大鼠高脂血症模型饲料的应用,用于构建大鼠高脂血症模型,其特征在于,连续给SD大鼠饲喂权利要求6所述的大鼠高脂血症的模型饲料15天,自由饮水,大鼠肝脏超过50%的肝细胞肿胀,形态不规则,排列紊乱,内充满的脂滴空泡,将细胞核挤向一侧,即大鼠高脂血症模型构建完成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010683023.2A CN111728096B (zh) | 2020-07-15 | 2020-07-15 | 大鼠高脂血症模型饲料及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010683023.2A CN111728096B (zh) | 2020-07-15 | 2020-07-15 | 大鼠高脂血症模型饲料及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111728096A true CN111728096A (zh) | 2020-10-02 |
CN111728096B CN111728096B (zh) | 2023-11-03 |
Family
ID=72654690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010683023.2A Active CN111728096B (zh) | 2020-07-15 | 2020-07-15 | 大鼠高脂血症模型饲料及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111728096B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112690367A (zh) * | 2020-12-29 | 2021-04-23 | 北京航空航天大学 | 两种不同营养素来源的高脂高蛋白饲料配方及其应用 |
CN113243466A (zh) * | 2021-07-01 | 2021-08-13 | 常州鼠一鼠二生物科技有限公司 | 斑马鱼高脂血症模型饲料及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102640725A (zh) * | 2011-02-17 | 2012-08-22 | 浙江中医药大学 | 一种高血压并发高脂血症大鼠模型的制备方法 |
CN103749385A (zh) * | 2014-01-20 | 2014-04-30 | 辽宁中医药大学 | 一种脾虚痰浊型高脂血症病证结合动物模型的制作方法 |
CN106234298A (zh) * | 2016-07-22 | 2016-12-21 | 浙江工商大学 | 一种短期内建立高脂血症大鼠模型的方法 |
CN107148941A (zh) * | 2017-04-07 | 2017-09-12 | 安徽农业大学 | 一种高脂血症模型的造模方法 |
-
2020
- 2020-07-15 CN CN202010683023.2A patent/CN111728096B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102640725A (zh) * | 2011-02-17 | 2012-08-22 | 浙江中医药大学 | 一种高血压并发高脂血症大鼠模型的制备方法 |
CN103749385A (zh) * | 2014-01-20 | 2014-04-30 | 辽宁中医药大学 | 一种脾虚痰浊型高脂血症病证结合动物模型的制作方法 |
CN106234298A (zh) * | 2016-07-22 | 2016-12-21 | 浙江工商大学 | 一种短期内建立高脂血症大鼠模型的方法 |
CN107148941A (zh) * | 2017-04-07 | 2017-09-12 | 安徽农业大学 | 一种高脂血症模型的造模方法 |
Non-Patent Citations (2)
Title |
---|
吴栩;韦伟标;刘少斌;: "高脂血症大鼠模型4种造模方法的筛选及优化" * |
陈美娟;邱服斌;张海杰;李雁津;李秀花;: "建立雄性SD大鼠高脂血症模型研究" * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112690367A (zh) * | 2020-12-29 | 2021-04-23 | 北京航空航天大学 | 两种不同营养素来源的高脂高蛋白饲料配方及其应用 |
CN113243466A (zh) * | 2021-07-01 | 2021-08-13 | 常州鼠一鼠二生物科技有限公司 | 斑马鱼高脂血症模型饲料及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN111728096B (zh) | 2023-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101669578B (zh) | 一种畜禽营养补充剂及其制备方法 | |
CN111728096A (zh) | 大鼠高脂血症模型饲料及其制备方法和应用 | |
CN103416608B (zh) | 灵长类实验型高脂饲料及其制备方法 | |
CN102669427B (zh) | 一种蛹草拟青霉发酵物饲料添加剂及其制备方法和应用 | |
CN102665704A (zh) | 用于伴侣动物的包含丙酮酸盐的组合物及其使用方法 | |
CN109303193A (zh) | 一种猫减肥粮及其制备方法 | |
CN101869214A (zh) | 一种原粮-颗粒料混合型饲料及其制备方法和应用 | |
CN105981987A (zh) | 一种可降低鸡蛋胆固醇含量的蛋鸡饲料及其制备方法 | |
CN103918914A (zh) | 一种野鸭速生饲料 | |
CN104705528A (zh) | 一种母猪专用复合维生素发酵中草药制剂及其制备方法和应用 | |
CN108464390A (zh) | 一种豆粕生物发酵饲料及其生产方法 | |
CN108634102A (zh) | 一种酶降解半乳甘露聚糖产品及其制备方法与应用 | |
Kamgang et al. | Cameroon local diet-induced glucose intolerance and dyslipidemia in adult Wistar rat | |
CN111328930A (zh) | 一种用于妊娠母猪的功能性预混合料及其制备方法 | |
CN106490307A (zh) | 一种微生物组合发酵浒苔的方法 | |
CN102106467A (zh) | 降低鸡蛋中胆固醇含量的饲料添加剂及其制备方法 | |
Gandarillas et al. | Associative effects between forages and concentrates on in vitro fermentation of working equine diets | |
CN109924345B (zh) | 一种利用中药残渣制备的海参饲料预混剂及其制备方法 | |
CN111772050A (zh) | 大鼠高尿酸血症模型饲料及其制备方法和应用 | |
CN113080331A (zh) | 一种人工鸽乳饲料及其制备方法 | |
CN102488090A (zh) | 利用废酵母泥制备的高蛋白饲料及方法 | |
CN101391061B (zh) | 一种抗生素替代物 | |
Widiyastuti et al. | Digestibility and blood metabolite profiles of chicken fed fermented Jatropha seed meal | |
CN106306346A (zh) | 不使用饲用抗生素的生猪饲养方法 | |
CN110403090A (zh) | 一种具有促生长和提高免疫力功能的鸡饲料及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |